ArticleScientific reports2017
Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 106 citations in OpenAlex.
- Salvaging the No-Reflow Zone: Intra-arterial Cranial Bone-Derived MSCs Restore Neurovascular Integrity After Stroke.Translational stroke research · 2026Article
- Bone marrow-derived mesenchymal stem cells for ischemic stroke: mechanisms, delivery strategies, clinical evidence, and translational challenges.Stem cell research & therapy · 2026Review
- Whole-body in vivo MPI cytometry reveals injection route-, dose-, cell size-, and disease-dependent differences in organ distribution.Science advances · 2026Article
- Potential of intranasal delivery of human mesenchymal stem cells and extracellular vesicles for stroke therapy.Acta biomaterialia · 2026Review
- Ligand-Driven Optimization of Iron Oxide Nanoprobes for In Vivo MRI Enhancement at Ultra-High Field.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Umbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.Stem cell research & therapy · 2025Review
- Mesenchymal stem cells therapy for immune thrombocytopenia in pregnancy: a case report.BMC pregnancy and childbirth · 2025Article
- Therapeutic potential of mesenchymal stem cells in neurodegenerative diseases.World journal of stem cells · 2025Review
- Intra-Arterial Administration of Stem Cells and Exosomes for Central Nervous System Disease.International journal of molecular sciences · 2025Review
- Advances in brain remodeling, stem cell therapies, and translational barriers in stroke and brain aging.Biogerontology · 2025Review
- Nose-to-brain delivery of stem cells in stroke: the role of extracellular vesicles.Stem cells translational medicine · 2024Review
- Therapeutic Applications of Engineered Mesenchymal Stromal Cells for Enhanced Angiogenesis in Cardiac and Cerebral Ischemia.Stem cell reviews and reports · 2024Review
- Cutting-edge regenerative therapy for Hirschsprung disease and its allied disorders.Surgery today · 2024Review
- Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic.Translational stroke research · 2024Review
- Probing Multiple Transplant Delivery Routes of CD+34 Stem Cells for Promoting Behavioral and Histological Benefits in Experimental Ischemic Stroke.Stem cells translational medicine · 2024Article
- Low molecular weight heparin decreases pro-coagulant activity in clinical MSC products.Cytotherapy · 2024Article
- Mesenchymal Stem Cell-Based Therapies in the Post-Acute Neurological COVID Syndrome: Current Landscape and Opportunities.Biomolecules · 2023Review
- Therapeutic potential of MSCs and MSC-derived extracellular vesicles in immune thrombocytopenia.Stem cell research & therapy · 2023Review
- Comparison of the Administration Route of Stem Cell Therapy for Ischemic Stroke: A Systematic Review and Meta-Analysis of the Clinical Outcomes and Safety.Journal of clinical medicine · 2023Review
- Fibrin-Targeted Nanoparticles for Finding, Visualizing and Characterizing Blood Clots in Acute Ischemic Stroke.Pharmaceutics · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) are a promising clinical therapy for ischemic stroke. However, critical parameters, such as the most effective administration route, remain unclear. Intravenous (i.v.) and intraarterial (i.a.) delivery routes have yielded varied outcomes across studies, potentially due to the unknown MSCs distribution. We investigated whether MSCs reached the brain following i.a. or i.v. administration after transient cerebral ischemia in rats, and evaluated the therapeutic effects of both routes. MSCs were labeled with dextran-coated superparamagnetic nanoparticles for magnetic resonance imaging (MRI) cell tracking, transmission electron microscopy and immunohistological analysis. MSCs were found in the brain following i.a. but not i.v. administration. However, the i.a. route increased the risk of cerebral lesions and did not improve functional recovery. The i.v. delivery is safe but MCS do not reach the brain tissue, implying that treatment benefits observed for this route are not attributable to brain MCS engrafting after stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.